Angèle Kelder
YOU?
Author Swipe
View article: CytoScan: Automated detection of technical anomalies for cytometry quality control
CytoScan: Automated detection of technical anomalies for cytometry quality control Open
Studies evaluating cellular phenotypes by cytometry techniques are increasingly facing analytical challenges due to the multitudes of samples and parameters that are evaluated concurrently. Spurious technical effects resulting from a lack …
View article: Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients Open
In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognosti…
View article: Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models
Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models Open
View article: The role of the primitive marker <scp>CD133</scp> in <scp>CD34</scp>‐negative acute myeloid leukemia for the detection of leukemia stem cells
The role of the primitive marker <span>CD133</span> in <span>CD34</span>‐negative acute myeloid leukemia for the detection of leukemia stem cells Open
The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. I…
View article: Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia Open
View article: Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML Open
Acute myeloid leukemia (AML) is a heterogeneous disease both in terms of genetics and clinical outcome.1 Patients can be subdivided into 3 risk groups using the European LeukemiaNet (ELN) prognostic risk classification with significantly d…
View article: Issue Information
Issue Information Open
View article: Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry Open
Background Measurable residual disease (MRD) assessed by multiparametric flow cytometry (MFC) has gained importance in clinical decision‐making for acute myeloid leukemia (AML) patients. However, complying with the recent In Vitro Diagnost…
View article: P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML Open
Background: Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) in bone marrow (BM) after two cycles of high-dose induction chemotherapy has strong prognostic value and predicts relapse when applied to patient…
View article: P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY. Open
Background: Measurable residual disease (MRD) is currently implemented to guide consolidation treatment in intermediate-risk AML. Optimization of MRD results is therefore crucial for clinical decision making. MRD can be detected by multipa…
View article: Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial Open
Contains fulltext : 293618.pdf (Publisher’s version ) (Open Access)
View article: AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML Open
Measurable residual disease (MRD) in AML, assessed by multicolor flow cytometry, is an important prognostic factor. Progenitors are key populations in defining MRD, and cases of MRD involving these progenitors are calculated as percentage …
View article: MRD Tailored Therapy in AML: What We Have Learned So Far
MRD Tailored Therapy in AML: What We Have Learned So Far Open
Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal survival, partly due to the frequent occurrence of relapse. Many patient- and leukemia-specific characteristics, such as age, cytogenetics, mutations, …
View article: Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients
Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients Open
Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disease characterized by heterotopic ossification (HO) that occurs in muscle tissue, tendons, and ligaments. The disease is caused by mutations in the Activin receptor type I (A…
View article: Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting Open
Summary Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia‐propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted…
View article: Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia
Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia Open
Half of the patients with acute myeloid leukemia (AML), who achieve complete remission after chemotherapy treatment, will ultimately experience a relapse. Measurable residual disease (MRD) is an important post‐treatment risk factor in AML,…
View article: Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults Open
A morphological examination incorporating a differential count of a recommended 500 nucleated bone marrow (BM) cells (Dohner et al, 2017) continues to be a requirement for a patient with acute myeloid leukaemia (AML) to be classified as in…
View article: Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible? Open
View article: Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Open
Response criteria in acute myeloid leukemia (AML) has recently been re-established, with morphologic examination utilized to determine whether patients have achieved complete remission (CR). Approximately half of the adult patients who ent…
View article: Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Open
Response criteria in acute myeloid leukemia (AML) has recently been re-established, with morphologic examination utilized to determine whether patients have achieved complete remission (CR). Approximately half of the adult patients who ent…
View article: Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization Open
Introduction: Measurable residual disease (MRD) in acute myeloid leukemia (AML) is a rapidly evolving area with many institutes embarking on it, both in academic and pharmaceutical settings. However, there is a multitude of approach…
View article: Absence of leukaemic <scp>CD</scp>34<sup>+</sup> cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered
Absence of leukaemic <span>CD</span>34<sup>+</sup> cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered Open
Summary Primary resistance and relapses after initial successful treatment are common in acute myeloid leukaemia and therefore outcome remains poor. More accurate risk group stratification and effective personalized risk adapted treatment …